CDC study shows effectiveness of RSV immunization for infants | CDC Online Newsroom | CDC – CDC

New data released today inCDCsMMWRshow thatnirsevimab, a long-acting monoclonal antibody product,was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).RSV is the leading cause of hospitalization among infants in the United States, and this finding supports CDCs recommendation to protectinfantsin their first RSV seasonby giving the infantnirsevimab if the mother did not receive the maternal RSV vaccine during pregnancy.

The current RSV season is the first time nirsevimab was available to protect infants from severe RSV, so the data released todayare the first United States estimatesofnirsevimabeffectiveness inprotectinginfantsagainst RSV-related hospitalizationin their first season of potential exposure to the virus.

The study looked at 699 infants from October 2023 through February 2024 using early data from CDCs New Vaccine Surveillance Network (NVSN), a population-based surveillance platform that monitors pediatric respiratory viruses to assess immunization effectiveness. Results show that nirsevimab was 90% effective at preventing RSV-associated hospitalization in infants during their first RSV season. These results reflect a shorter surveillance period due to the introduction of this new product in August 2023. Nirsevimab effectiveness may be lower over a full RSV season (October through March in most of the United States). With increasing availability of nirsevimab in future RSV seasons, CDCwill assess its effectiveness over an entire season.

RSV prevention products remain our single most important tool to protectinfants from RSV. Healthcare providers should recommendeither:

CDCcontinues to monitorthe safety andeffectivenessof nirsevimab and maternal RSV vaccines.

Go here to read the rest:

CDC study shows effectiveness of RSV immunization for infants | CDC Online Newsroom | CDC - CDC